Nita Ahuja, MD, MBA is the William H. Carmalt Professor of Surgery and Chair of the Department of Surgery, Yale School of Medicine and Surgeon-in-Chief at Yale New Haven Hospital. She is a national and international surgical leader and surgeon scientist with specializations in gastrointestinal cancers, including gastric, colorectal, and pancreatic cancers. She has an international reputation for the management of peritoneal cancer metastases with cytoreduction and heated intraperitoneal chemotherapy. Dr. Ahuja, a board-certified surgeon, obtained her medical education at Duke University, School of Medicine. She received her training in general surgery at Johns Hopkins where she also completed a fellowship in surgical oncology that focused on hepatobiliary malignancies. Dr. Ahuja obtained an Executive MBA from Johns Hopkins Carey School of Business. In 2003, she joined the faculty at Johns Hopkins. While there, she directed the multidisciplinary programs in soft tissue sarcoma and gastric cancers and lead the integration and expansion of surgical oncology programs across the Johns Hopkins health system. During her time there, she became one of their most accomplished faculty members. Her positions at Johns Hopkins included serving as Division Chief of Surgical Oncology and Vice Chair of Academic Affairs for the Department of Surgery. Dr. Ahuja also served as the Director of the Peritoneal Surface Malignancy Program, Director of Soft Tissue Sarcomas and Co-Director of Gastric Multidisciplinary Clinic. She also served as the Associate Director of Surgical Oncology for the Sidney Kimmel Comprehensive Cancer at Johns Hopkins.
Dr. Peter J. Allen is the Vice Chair of Surgical Services, and Murray F Brennan Professor of Surgery, at Memorial Sloan Kettering Cancer Center. He also serves as the Associate Director of Clinical Programs within the David Rubenstein Center for Pancreatic Cancer Research. He is originally from the state of Maine, received his undergraduate degree at Harvard University, and his medical degree from Dartmouth. Dr Allen performed his general surgical residency at Walter Reed Army Medical Center in Washington D.C. During this time he performed a research fellowship in the laboratory of Murray Brennan at Memorial Sloan-Kettering Cancer Center. Following residency, Dr. Allen performed a clinical fellowship at Memorial Sloan-Kettering Center and then returned to Walter Reed where he was an attending surgeon on the surgical oncology service. During his time as a surgical attending at Walter Reed, Dr. Allen was deployed to Iraq where he spent one year as a surgeon on a forward surgical team. Dr. Allen returned to Memorial Sloan-Kettering Cancer Center in 2005, and since that time he has lead the surgical efforts in the treatment of neoplastic diseases of the pancreas. His clinical and research efforts have been focused on the development of novel diagnostic and therapeutic approaches to invasive and pre-invasive lesions of the pancreas. He has led multiple prospective clinical trials, and his research has been funded by numerous organizations including the SSO and the NIH.
REIKO ASHIDA, M.D., Ph.D
Departments of Cancer Survey and Gastrointestinal Oncology
Osaka International Cancer Institute, Osaka, Japan
Reiko Ashida is currently Co-Director of Departments of Cancer Survey and Gastrointestinal Oncology at Osaka International Cancer Institute, Osaka, Japan. She graduated medical school in 1998 and obtained PhD in 2005 from the Graduate School of Medicine, Osaka City University. She started EUS since 1999 and trained EUS-FNA in 2002 at Aich Cancer Center and had the advanced fellowship program of Interventional EUS at University of California Irvine, Medical Center between 2007-2009. Her research interests include early detection and treatment of pancreatic cancer, Interventional EUS, and development of EUS-guided high intensity focused ultrasound (EUS-HIFU) with novel phase change nanodroplets as a sensitizer. She has received several awards and grants related to ultrasound technology from Japan Society of Ultrasonics in Medicine.
Prof. Claudio Bassi is Full Professor and Chairman of General and Hepato-Bilio-Pancreatic Surgery Department. Professor in several degree courses, he directs the School of Specialization in General Surgery at the University of Verona and is responsible for the Translational Surgery Laboratory for Medical Research (LURM). Prof. Bassi’s experience covers all surgical pathologies of the pancreas and the scientific activity was entirely dedicated to pancreatic diseases. Prof. Bassi has an H-Index: 75 (updated at 21/02/2018 (Source SCOPUS)) and he’s author of more than 350 publications up to date, was Invited Speaker in over 300 national and international congresses and performed more than 2000 pancreatic resections and more than 8000 major surgery intervenctions.
Angela Belcher is a biological and materials engineer with expertise in the fields of biomaterials, biomolecular materials, organic-inorganic interfaces and solid-state chemistry and devices. Her primary research focus is evolving new materials for energy, electronics, the environment, and medicine. She received her B.S. in Creative Studies with an emphasis in biology from The University of California, Santa Barbara. She earned a Ph.D. in inorganic chemistry at UCSB in 1997. Following her postdoctoral research in electrical engineering at UCSB, she joined the faculty at The University of Texas at Austin in the Department of Chemistry in 1999. She joined the faculty at MIT in 2002. Some recent awards include 2018 NAE (National Academy of Engineers) Fellow, 2015 NAI (National Academy of Inventors) Fellow, the 2013 $500,000 Lemelson-MIT Prize for her Inventions, 2010 Eni Prize for Renewable and Non-conventional Energy, in 2009 Rolling Stone Magazine listed her as one of the top 100 people changing the country.
Professor Andrew Biankin is the Regius Chair of Surgery at the University of Glasgow a Cancer Research UK Clinician Scientist, a Wellcome Trust Senior Investigator, a Fellow of the Royal Society of Edinburgh and The Academy of Medical Sciences. He is the Director of the Wolfson Wohl Cancer Research Centre which is focused on precision oncology. He plays leadership roles in national and international consortia in cancer therapeutic development. He has authored over 150 articles in major journals including seminal works on pancreatic cancer, genomics and precision medicine. He works closely with industry and biotech companies to develop innovative interventions for pancreatic cancer.
Dr. Jonathan Brody is currently the Director of Surgical Research and Co-director of the Jefferson Pancreatic, Biliary, and Related Cancer Center. He is also a member of the Kimmel Cancer Center (with a leadership role in GI Program) and a Professor within the departments of Surgery and Pathology. Dr. Brody received his Ph.D. from The Johns Hopkins University School of Medicine, and his thesis specialized in studying the molecular aspects of cancer and cancer genetics. He patented, with Dr. Scott Kern, novel buffers for DNA identification (DNA electrophoresis buffer), that have changed the format of this molecular biology technique used to detect DNA. He was elected Chair of the Cancer Research Program (PRCRP), Department of Defense council and serves on many international study sections, including currently being the Chair of the Tumor Biology and Genomics study section for the American Cancer Society and NCI study section panels. He has published over 100 peer review publications in many top tier scientific and cancer journals. Additionally, he was an American Cancer Society Research Scholar, is NIH (NCI, R01) funded, and won the American Association of Cancer Research, Pancreatic Cancer Career Development Award in 2010. His lab focuses on many molecular aspects of pancreatic cancer, including developing ways to target a novel pro-survival network in pancreatic cancer cells and optimizing current therapies used in the clinic. His also has an interest in personalizing therapy for pancreatic cancer patients (PanCAN, RAN grant PI).
Prof. dr. Marco J. Bruno (1963) is a full professor of Gastroenterology & Hepatology and chief of the department of Gastroenterology & Hepatology at the Erasmus Medical Centre in Rotterdam. He received his training at the Academic Medical Centre in Amsterdam under the supervision of Prof. dr. Guido Tytgat and Prof. dr. Kees Huibregtse. His clinical and research activities focus on gastrointestinal oncology, hepato-pancreato-biliary diseases and interventional endoscopy, including endoscopic retrograde cholangiopancreatography (ERCP) and endoscopic ultrasound (EUS). He (co)-author of numerous peer reviewed articles in high ranking journals including the New England Journal of Medicine, Gastroenterology, Gut, Endoscopy and Gastrointestinal Endoscopy. He is a recognized international authority on the diagnosis and treatment of biliary and pancreatic diseases and has served as invited faculty at many international conferences and live endoscopy workshops. He is council member end treasurer of the European Association of Gastroenterology, Endoscopy & Nutrition (EAGEN); past council member of United European Gastroenterology (UEG); and past chairman of the Education Committee of United European Gastroenterology (UEG) and the Dutch Pancreatitis Study Group.
Erasmus Medical Center and department of Gastroenterology & Hepatology
The Erasmus Medical Center is a large tertiary care 1320 bed academic hospital located in the city of Rotterdam the Netherlands. The department of Gastroenterology & Hepatology employs 17 staff members covering all the relevant GI & H specialty areas including hepatology (hepatitis, hepatocellular carcinoma, and liver transplantation), advanced endoscopy, GI oncology (esophageal, stomach, pancreas and colon), and inflammatory bowel disease & intestinal ischemia. The department has 21 fellows in training to become gastroenterologists and 2 foreign fellows for advanced endoscopy training. The department has its own dedicated laboratory facilities for translational and basic research. In total 40 PhD students are working to complete their PhD thesis on various clinical, translational and basic research topics covering the various focus areas of the department.
Richard Burkhart is an assistant professor of surgery at Johns Hopkins Hospital with a focus on cancers of the pancreas, liver and bile ducts. Dr. Burkhart received his medical degree from Boston University, completed his surgical residency at Thomas Jefferson University Hospital, and completed a fellowship in surgical oncology at Johns Hopkins. His research training has focused on pancreatic cancer biomarkers, tumor modeling, and therapeutic testing and includes fellowships at Thomas Jefferson University hospital and the Cold Spring Harbor Laboratory. His clinical focus is on complex minimally-invasive approaches to treat oncologic diseases of the pancreas, liver, and biliary tree. His current research focuses on precision medicine initiatives in pancreatic cancer care. He has a particular interest in using personalized models of pancreas cancer, made from a tumor after surgical resection, to select optimal adjuvant chemotherapeutics for each patient.
Marcia (aka Mimi) was born and raised in Manila, Philippines. After graduating summa cum laude at the University of the Philippines Medical School in 1985, she completed fellowship training in Gastroenterology at Johns Hopkins. After advanced endoscopic training in Cleveland, she returned to Johns Hopkins Hospital in 1996 as the first woman director of therapeutic endoscopy and endoscopic ultrasonography, quickly achieving international recognition as a multi-talented academic endoscopist in a male-dominated subspecialty. She was promoted to professor of medicine and oncology in 2011 as a clinical investigator, program builder, mentor, and clinician. Her research involves therapeutic endoscopy, advanced endoscopic imaging, and endoscopic ultrasonography. She is a world authority on screening and early detection of pancreatic cancer in high risk individuals. She organized and co-directs (with Michael Goggins) the Johns Hopkins Cancer of the Pancreas Screening (CAPS) clinical and translational research program and the multidisciplinary International CAPS Consortium for worldwide collaboration on pancreatic cancer screening and early detection. With a group of international experts, she organized the first CAPS Consortium Summit in Baltimore and co-authored the first CAPS Consensus paper in 2012.
Dr David Chang is a surgeon scientist who specialises in the treatment of malignant pancreatic diseases. His research interest is on the development and implementation of novel therapeutic strategies for pancreatic cancer utilising molecular biomarkers of prognosis and therapeutic responsiveness. He is the co-lead of Precision-Panc, a pan-UK initiative to deliver personalized cancer care for pancreatic cancer, and is the chief investigator of its Master Protocol. He is also involved in Precision Promise, a Pancreatic Cancer Action Network (USA) initiative dedicated in delivering personalized treatment for patients with pancreatic cancer. In addition, he serves on the scientific planning committee of ICGC for Medicine (ICGCmed), to shaping the goals and the future of the next generation International Cancer Genome Consortium (ICGCmed) projects to realize the goals and promises of precision medicine.
Dr. Roberto Coppola is Full Professor of Surgery at the Campus Bio-Medico University School of Medicine in Rome. Chief of the Department of General Surgery and Director of the Residency School in General Surgery at the same University. He is a Member of the Ethical Committee of the Catholic University of Rome since 1999. His main field of research and clinical activity is surgery of the pancreas.
Dr. Coppola became a Fellow of the American College of Surgeons in 1996 and has been a Fellow of the Italian Society of Surgery since the beginning of his career. He was the Director of several international meetings on Pancreas Cancer in Italy.
His recent fields of research are the standardization of the resection margins in pancreatic surgery, the impact of nosocomial infections in pancreatic surgery and the new applications of nanotechnology to pancreas cancer.
Dr. Coppola is in the editorial board of International Journal of Surgery, and Pancreatology.
Marco Del Chiaro
Professor Marco Del Chiaro is Associate Professor and head of the Pancreatic Surgery Unit at Division of Surgery (CLINTEC), Karolinska Institutet. He is revisor of the European Pancreatic Club, member of the UEG General Assembly, member of the council of the International Association of Pancreatology, member of the EU Pancreas study group. Marco Del Chiaro is also the founder of the Italian Registry for Familial Pancreatic Cancer, of the European Study Group on Cystic Tumors of the Pancreas and of the Nordic Study Group on Cystic Tumors of the Pancreas. He is a member of editorial boards of International scientific journals (i.e. JAMA Surgery) and author of more than 600 scientific publications including 124 peer review papers.
Luis Diaz Jr
Dr. Luis Diaz is a leading authority in oncology who has pioneered several genomic diagnostic and therapeutic approaches for cancer. He is head of the Division of Solid Tumor Oncology at the Memorial Sloan Kettering Cancer Center where he specializes in the treatment of advanced pancreatic and colorectal cancers. Prior to his role at MSKCC, he was a member of the Ludwig Center for Cancer Genetics and Therapeutics at Johns Hopkins and also directed the Swim Across America Lab. He is also founder of several entities that focus on genomic analyses of cancers including Inostics, PapGene and Personal Genome Diagnostics (PGDx). Dr. Diaz has undergraduate and medical degrees from the University of Michigan, and completed residency training at the Osler Medical Service at Johns Hopkins and medical oncology training at the Sidney Kimmel Cancer Center at Johns Hopkins.
More recently, his work has involved the clinical development of tumor-derived DNA as a biomarker for cancer screening, early detection, monitoring and measurement of early residual disease. The basis of this work is based on the well-accepted premise that cancer is defined by a discrete set of genetic alterations. This approach combines a next-generation genomic sequencing with novel digital techniques to count tumor-derived DNA fragments in complex mixtures of DNA. The mutations found in cancers are never found in normal cell populations and detection of these mutations therefore confers exquisite specificity to the assay. Accordingly, he demonstrated that the level of mutations in the circulation, also known as circulating tumor DNA (ctDNA), tracked with fluctuations in tumor burden in patients undergoing resective surgery for colorectal cancer. Most striking is the ability of ctDNA to accurately predict recurrence after surgery and monitor patients with undetectable CEA levels. This novel biomarker is based on personalized genomics that in essence provides a ‘viral load’ equivalent for patients with solid tumors. The preliminary studies served as the basis for his most recent invention, the ‘molecular pap smear’, which is a promising approach for the early detection of ovarian and endometrial cancers.
He has also harnessed the power of cancer mutations as potent antigens and championed the use of checkpoint inhibitors in the treatment of patients with tumors with high mutational burden. His landmark proof-of this principle study used PD-1 blockade in patients with mismatch repair deficiency and showing dramatic and potentially curative responses more than 50% of metastatic patients, which resulted in the first historic FDA approval of a cancer treatment for any solid tumor in adults and children with a specific genetic feature.
He is a member of the groups that received the 2013 AACR Team Science Award for Pancreatic Cancer Sequencing Team, the 2014 AACR Team Science Award for Malignant Brain Tumor Team and the 2017 AACR Team Science Award for Liquid Biopsies. He is also the leader of the 2017 SU2C Colon Cancer Dream Team. In addition, his work has been highlighted in several scientific and lay media outlets including the Diane Rehm Show, New York Times, NPR, CNN and the NBC nightly news.
Dr. Michael Erdek is Associate Professor of Anesthesiology and Critical Care Medicine and Oncology at The Johns Hopkins University School of Medicine and Adjunct Associate Professor at the Berman Institute of Bioethics. Dr. Erdek received his undergraduate medical education at the University of Pennsylvania, where he was a Walter Lewis Croll Scholar. He trained in Surgery and in Anesthesiology prior to completing his subspecialty training in Pain Medicine and Critical Care Medicine at The Johns Hopkins University.
Dr. Erdek has published and lectured extensively in the field of Pain Medicine, and has been appointed to the Polyanalgesic Consensus Panel and has received the National Pancreas Foundation Compassionate Care Award. He is a member of the editorial boards for several journals in the field of Pain Medicine.
His interests center on interventional pain management of cancer pain, intrathecal therapy for spasticity, and spinal cord stimulation for neuropathic pain and vascular disease.
Dr. Eshleman received his MD and PhD (cell biology) degrees from the University of Pennsylvania in 1988. He completed an internship in Internal Medicine and residency in Clinical Pathology. He joined the laboratory of Dr. Sandy Markowitz at Case Western Reserve University where he demonstrated that colon cancers with microsatellite had highly elevated mutation frequencies. He joined the faculty at Hopkins in 1997 where he has focused his work on the genetics of pancreatic cancer. His interests include early detection, minimal residual disease monitoring and pancreatic cancer predisposition genes. He also contributes to the Molecular Pathology clinical service.
Dr. Massimo Falconi is currently Full Professor of Surgery and Chairman of the Pancreatic Unit at the University Vita e Salute, San Raffaele Hospital IRCCS, in Milan, Italy. He studied medicine at the University of Verona, specializing in general surgery, gastroenterology and endoscopy. He has participated in international medical research projects in such diverse places as Germany, Spain, Ecuador, and Japan. A member of many medical societies, including IAP, EPC, ENETS and I and EAHPBA. Prof Falconi is currently on the executive committees of both ENETS and IAP. He has written more than 300 peer-reviewed articles and currently reviews articles for the following publications: Annals of Oncology, British Journal of Surgery, Cochrane, Gut, Lancet, Neuroendocrinology, Nutrition, Pancreas, Pancreatology, Journal of Endocrinological Investigation (JEI), Journal Of the Pancreas (JOP), Surgery, Annals of Surgery. Dr. Falconi serves as Associate Editor for the section of the pancreas and neuroendocrine tumors for Digestive and Liver Disease, official journal of the Italian and French Gastroenterological societies. He is also editorial member of the following journals: World Journal of Gastroenterology, subject Area Editor of The International Journal of Biological Markers and of International Journal of Endocrine Oncology. He has an impact factor calculated on the basis of JCR 2014 of more than 1,500 and his h index on Scopus is 61.
Carlos Fernandez-del Castillo
Dr. Carlos Fernandez-del Castillo was born in grew up in Mexico City, attended medical school at the National Autonomous University of Mexico, and then did a residency in internal medicine and surgery at the Instituto Nacional de la Nutricion. In 1989 he came to the Massachusetts General Hospital as a Research Fellow in the Pancreatic Research Laboratory of Dr. Andrew Warshaw, and in 1991 joined the staff in the Division of General/GI Surgery. He is currently the director of the Pancreas and Biliary Surgery Program, co-director of the GI Cancer Center, and the Jorge and Darlene Perez Endowed Chair in Surgery at the MGH, as well as a Professor of Surgery at Harvard Medical School. For several years he has performed the largest number of pancreatic resections in the state of Massachusetts.
He has authored over 230 original articles and 100 book chapters and reviews, mostly on topics related to surgical diseases of the pancreas. He currently holds NIH funding for the study of the fluid of cystic neoplasms of the pancreas. Dr. Fernandez-del Castillo has been recipient of multiple teaching awards, and in 2016 was recognized with the Andrew L. Warshaw Master Educator Award given by the SSAT. He was also recipient of the 2011 Brian McGovern award for Clinical Excellence, given by the MGPO, and is currently a member of its board of trustees. He is member of many medical associations, and a former president of the American Pancreatic Association.
Dr. Elliot K. Fishman is Director of Diagnostic Imaging and Body CT at Johns Hopkins Hospital, where he is Professor of Radiology, Surgery, Urology and Oncology. Dr. Fishman’s clinical and research interests have focused on advanced medical imaging with specific emphasis on CT and 3-Dimensional imaging. Recent emphasis has also been focused on Deep Learning in Medical Imaging as Co-PI of the Felix Project for Early Detection of Pancreatic Cancer. Dr. Fishman’s work in CT has resulted in over 1200 peer reviewed publications, and he has been the co-author of 10 textbooks. Dr. Fishman’s research team has been one of the leading groups in developing new techniques and technologies, whether in visualization or post processing or in education. Dr. Fishman has expertise in computer and web-based education, developing the website, www.ctisus.com, which currently has over 300,000 users, as well as its Facebook version which has over a million followers from over 190 countries. Dr. Fishman and his team have also developed 14 iPad programs for the Apple store.
Dr. Furukawa is currently Professor and Chairman of Department of Histopathology, Tohoku University Graduate School of Medicine, Sendai, Japan. He graduated Faculty of Medicine, Akita University, Akita, Japan, in 1986. He conducted his doctoral research at Department of Pathology, Research Institute for Tuberculosis and Cancer, Tohoku University, Sendai, Japan, and received PhD degree from Tohoku University in 1993. He did his postdoctoral research at Montreal General Hospital Research Institute, Montreal, PQ, Canada, from 1993-95. He had been an assistant professor of Department of Molecular Pathology, Tohoku University Graduate School of Medicine in 1996-2005, an associate professor of International Research and Educational Institute for Integrated Medical Sciences, Tokyo Women’s Medical University, Tokyo, Japan, in 2005-2008, and a professor of Institute for Integrated Medical Sciences, Tokyo Women’s Medical University in 2008-2017. He has been appointed to the current position from 2017. He received a number of awards including Government of Canada Award (1994), Pathology Research Award of the Japanese Society of Pathology (2002), and the Hirshberg Award for Pancreatic Cancer Research (2009). His research interests include the molecular pathobiology of pancreatobiliary neoplasms. His publications can be found at the following URL: http://scholar.google.com/citations?user=aQRfR_QAAAAJ&hl=ja&oi=ao.
Dr. Junji Furuse currently works as a Professor, Department of Medical Oncology, Kyorin University Faculty of Medicine, Japan.
In 1984, graduated from Chiba University of Medical School and then attended the First Department of Internal Medicine, Chiba University.
In July, 1992- February, 2008: Division of Hepatobiliary Pancreatic Medical Oncology, National Cancer Center Hospital East
March, 2008-present: Professor, Department of Medical Oncology, Kyorin University School of Medicine.
Japanese Clinical Oncology Group (JCOG): Chair of Hepatobiliary and Pancreatic Oncology Group
Japan Pancreas Society (JPS): Director, Chair of health insurance committee
International Association of Pancreatology Council Member
ASCO Active member
ESMO Active member
Gastrointestinal Medical Oncology, especially hepatobiliary and pancreatic cancer.
Dr Steven Gallinger is an Hepatobiliary/pancreatic (HPB) surgical oncologist and member of the GI Site Cancer Program at Princess Margaret Cancer Centre. He is Professor of Surgery at the University of Toronto, and Head of the HPB Surgical Oncology Program at UHN and MSH. His research interests are primarily in the area of GI cancer genetics and he is co-Director of the Centre for Cancer Genetics at the Samuel Lunenfeld Research Institute, and co-PI of the Zane Cohen Familial Gastrointestinal Cancer Registry at MSH. He is also PI of the Ontario Pancreas Cancer Study, a member of the NIH funded Pancreas Cancer Genetic Epidemiology consortium, a population-based registry of pancreas cancer cases and their families which is now integrated with the International Cancer Genome Consortium at the OICR where he is Head of the Translational Research Initiative in pancreas cancer, termed PanCuRx. Dr. Gallinger also co-leads (with Dr. Jennifer Knox) the McCain Centre for Pancreas Cancer which supports the rapid diagnostic and treatment program at UHN.
Dr. Goggins is a Professor of Pathology, Medicine and Oncology at The Johns Hopkins University School of Medicine where he directs the Pancreatic Cancer Early Detection Research Laboratory. He is the Sol Goldman Professor of Pancreatic Cancer Research. He is an Attending Physician and Gastroenterologist at Johns Hopkins Hospital. His early detection research focuses on evaluating the potential clinical utility of measuring markers of early pancreatic cancer in pancreatic fluids and blood. He is the principal investigator of the multicenter Cancer of the Pancreas Screening-5, (CAPS5) study. He is supported by R01 and U01 grants from the National Cancer Institute. As a member of the pancreatic cancer research team at Johns Hopkins University, he was awarded the 2012 AACR Team Science award.
Thomas M.Gress, MD,
Chair of Gastroenterology and Director of the Department of Gastroenterology, Endocrinology,
Metabolism and Infectiology, Philipps University of Marburg, 35043 Marburg, Germany
Phone: + 49-6421- 586-6460
Thomas Gress completed his medical degree at the Philipps-University of Marburg in Germany, where he started his training in Internal Medicine and his basic research on pancreatic diseases. He performed a postdoctoral fellowship at the Genome Analysis laboratory at CR-UK in London (UK). Thereafter he moved to the University of Ulm in Germany where he completed his training in Internal Medicine and Gastroenterology and founded his research group working on translational and functional genome analyses in pancreatic cancer. Later he was appointed Professor of Gastroenterology at the University of Ulm and in 2006 Chair of Gastroenterology and Director of the clinical department of gastroenterology, endocrinology, metabolism and infectiology at the Philipps University of Marburg. His research covers translational and clinical aspects in pancreatology and gastrointestinal oncology, his department being a major referral center for GI-tumours and in particular pancreatic cancer and neuroendocrine tumours. He is the gastroenterologists of the Familial Pancreatic Cancer Registry (FaPaCa), one of the biggest European registries for familial pancreatic cancer, and coordinator of the Marburg ENETS-center of excellence for neuroendocrine tumours. He is associate editor for pancreatic diseases of the Journal “GUT”.
Robert Grützmann is currently full Professor of surgery and Chairman of the Department of Surgery, University Hospital Erlangen, Germany. His main interest clinically as well as scientifically is pancreatic cancer, cystic and neuroendocrine tumors of the pancreas as well as chronic pancreatitis. He has published over 150 peer-reviewed papers.
Jin He, M.D., Ph.D., is an assistant professor of surgery at the Johns Hopkins University School of Medicine. He is a surgical oncologist specializing in tumors from the Hepato-Pancreato-Biliary organs. He performs open as well as minimally invasive (robotic and laparoscopic) surgery, including the Whipple procedure.
Dr. He received his medical degree from Beijing Medical University and a Ph.D. in oncology from Fudan University Shanghai Medical College. He completed the Halsted general surgery residency training at Johns Hopkins, followed by a ACGME accredited fellowship in complex general surgical oncology at Johns Hopkins.
Dr. He’s research focuses on personalized treatment through stratifying pancreatic tumors on their genetic features. He holds several patents in anti-cancer vascular targeting agents and has published extensively in peer-reviewed journals and lectured internationally. He serves on several national committees including the NCCN panel on neuroendocrine tumors and the Alliance for Clinical Trials in Oncology.
Dr. Herman is currently a Professor and Division Head ad-interim in the Department of Radiation Oncology at The University of Texas MD Anderson Cancer Center. He specializes in the treatment of pancreatic and hepatobiliary malignancies. Dr. Herman has been a writing member for the NCCN and ACR, AJCC guidelines committees and is currently on the medical advisory board for the pancreatic cancer action network and member of the NIH neuroendocrine and pancreas task forces. He serves as principal investigator for several institutional gastrointestinal protocols and a co-investigator (radiation oncology lead) for the Alliance borderline resectable cancer trial which is evaluating the role of SBRT. His major areas of clinical and basic research involve identification of novel biomarkers and integration of stereotactic body radiation therapy (SBRT) with immunotherapy and targeted therapies.
Dr. Ralph Hruban is a Professor of Pathology and Oncology, the Director of The Sol Goldman Pancreatic Cancer Research Center, and the Baxley Professor and Director of the Department of Pathology at the Johns Hopkins University School of Medicine. He received his undergraduate degree from the University of Chicago and is a 1985 Johns Hopkins School of Medicine alumnus. He completed his residency training at Hopkins and he spent one year as a Fellow at Memorial Sloan-Kettering Cancer Center in New York. After completing his fellowship, Dr. Hruban returned to Johns Hopkins in 1990 to join the faculty.
Dr. Hruban has received numerous awards including the Team Science Award from the American Association for Cancer Research (2013 and 2017). He is a member of the German National Academy of Sciences Leopoldina. In addition to his research efforts, Dr. Hruban created the Johns Hopkins Pancreatic Cancer Web Page (http://pathology.jhu.edu/pc ).
Dr. Matthew HG Katz is currently Associate Professor, Chief of the Pancreatic Surgery Service and Vice Chair for Research in the department of Surgical Oncology at the University of Texas MD Anderson Cancer Center. His clinical and research interests focus on patients with pancreatic cancer. He has extensive experience in the design and conduct of clinical trials has led two national cooperative group studies of the effects of preoperative therapy on patients with advanced pancreatic cancer. He has published over 130 original articles that have described novel multi modality treatment approaches for patients with this disease. He has a thriving pancreatic surgery clinical practice.
Michael L. Kendrick, M.D.
Professor of Surgery, Mayo Clinic College of Medicine and Science
Chair, Division of Hepatobiliary and Pancreas Surgery
Consultant, Division of Hepatobiliary and Pancreas Surgery
Program Director, Advanced GI Minimally Invasive Surgery Fellowship
Dr. Michael Kendrick is Professor of Surgery at the Mayo Clinic in Rochester, Minnesota. He received his M.D. degree from George Washington University in Washington, DC. Doctor Kendrick completed his general surgery residency at the Mayo Clinic College of Medicine in Rochester, Minnesota. After residency, he received additional training as a Mayo Foundation Scholar in hepatobiliary surgery at the Mayo Clinic and in minimally invasive surgery at Mount Sinai in New York. His surgical interests include laparoscopic and open management of pancreatic and hepatobiliary diseases. Doctor Kendrick has published 20 book chapters and 151 peer-reviewed articles in the literature. He was named “Teacher of the Year in Surgery” for several years. He serves on multiple society and institutional committees and is the Chair of the Mayo Surgical Facilities Subcommittee.
Doctor Kendrick is currently Chair of the Division of Hepatobiliary and Pancreas Surgery, and Director of the Advanced GI Minimally Invasive Surgery Fellowship Program at Mayo Clinic Rochester.
MASAYUKI KITANO, MD, PhD
Second Department of Internal Medicine, Wakayama Medical University, Japan
Dr. Masayuki Kitano graduated Tottori University School of Medicine, got medical degree in Japan in 1990 and earned PhD in 1994. From 2000, he began to work at Kinki University, and studied in the field of pancreatobiliary diseases, particularly endoscopic diagnosis and treatment. In 2016, he became a chairman and professor of Second Department of Internal Medicine (Gastroenterology), Wakayama Medical University. He and his colleagues made a novel EUS system equipped with contrast harmonic imaging which allowed visualization of tissue microcirculation, and reported role of EUS for diagnoses of pancreatobiliary and gastrointestinal diseases, particularly of small pancreatic cancers. By these works, he received the Ito Award from Japan Society of Ultrasonics in Medicine. He works as a faculty of the Japanese Society of Gastroenterology, of the Japan Gastroenterological Endoscopy Society, of the Japan Pancreas Society and of Japan Society of Ultrasonics in Medicine. He has authored / co-authored 172 peer reviewed English publications.
Dr. Kozarek completed his gastroenterology fellowship at the University of Arizona-Phoenix VA Medical Center in 1978. He has been a member of the Section of Gastroenterology at Virginia Mason Medical Center since 1983, serving as Chief of GI for 15 years and currently as the Executive Director of the Digestive Disease Institute at Virginia Mason, as well as Clinical Professor of Medicine at the University of Washington.
In a career spanning more than 40 years, Dr. Kozarek has contributed over 500 scientific papers, invited reviews, editorials, book chapters, as well as 12 medical texts to the medical literature on topics ranging from therapeutic endoscopy, inflammatory bowel diseases and practice economics. He is a past president of the American Society of Gastrointestinal Endoscopy (ASGE), and was the 2005 recipient of the ASGE’s highest honor, the Schindler Award. Dr. Kozarek has served as the President of the Society for Gastrointestinal Intervention (SGI) and is a past president of the World Gastroenterology Organization (WGO).
Dr. Dung Le is an associate professor at the Sidney Kimmel Comprehensive Cancer Center at the Johns Hopkins University in Baltimore, Maryland. She is a member of the Gastrointestinal Malignancies Division of Medical Oncology.
Dr. Le received her undergraduate degree at Yale University and underwent internal medicine and oncology fellowship training at Johns Hopkins University. Her research interests include novel approaches to patients with gastrointestinal malignancies. Her main research focuses are on combination immunotherapy strategies or the use of predictive biomarkers to improve responses to immunotherapy. She has helped lead the development of programmed death-1 (PD-1) blockade in tumors with mismatch repair deficiency across disease types which led to the first biomarker selection tissue agnostic FDA approval. She is also testing multiple combinations with immune checkpoint blockade in the hopes of improving responses to immunotherapy in gastrointestinal malignancies.
Lindsey Manos, DHSC, PA-C is a Lead Physician Assistant for the Hepatobiliary and Pancreas Surgery and Surgical Oncology Divisions at The Johns Hopkins Hospital. Lindsey is the Clinical Coordinator of The Johns Hopkins Multidisciplinary Pancreatic Cyst Program. Lindsey is certified by the National Commission on Certification of Physician Assistants and has a Doctor of Health Science degree, with a concentration in Organizational Behavior.
Dr. Miao Yi, obtained his PhD from University of Leuven, Belgium (K.U.Leuven). He is Professor of Surgery, Chief Physician and Doctoral Tutor, and heenjoyed special government allowances from the State Council. He is the Chair of Department of Surgery, Nanjing Medical University. He is also Director of both Pancreas Center of The First Affiliated Hospital with Nanjing Medical University and the Institute of Pancreas of Nanjing Medical University. He is the Vice President of Chinese Pancreatic Surgery Association. He is also the Fellow of American College of Surgeons (FACS), the Fellow of Royal College of Surgeons in England (FRCS) and honorary Fellow of the International College of Surgeons (FICS(Hon)). He is the Standing Deputy Chief of Editor of “Chinese Journal of Digestive Surgery” and “China Journal of Practical Surgery”. Besides, He is the Editor of “Chinese Journal of Surgical Journal”, “Annals of Surgery Chinese Edition” and “Langenbeck’s ARCHIVES OF SURGERY”.
Quintus Molenaar is a professor of Hepato-Pancreato-Biliary Surgery at the Regional Academic Cancer Center Utrecht and the University Medical Center Utrecht, the Netherlands and is leading the HPB program performing approximately 200 HPB operations per year.
He is Co-founder and Board Member of the Dutch Pancreatic Cancer Group, Co-founder and Board Member of the Dutch Pancreatic Biobank, Board Member of the Dutch Hepato-Pancreato-Biliary Association and Member of the Research Commission of the Dutch Steering Group Liver Surgery.
He is Principal Investigator of several national studies on the treatment of patients with resectable, locally advanced and recurrent pancreatic cancer.
He is (co-) author of over 100 peer-reviewed papers and chapters in textbooks.
Dr. Masafumi Nakamura is Professor at the Department of Surgery and Oncology of the Kyushu University, Fukuoka, Japan. He trained in Kyushu University, National Cancer Center, and Harvard University, and was appointed as the Chairman and Professor of Kawasaki Medical School before returning to Kyushu University. He is the President of Japanese Society for Endoscopic Pancreatic Surgery, Director of Japanese Society of Hepato-Biliary-Pancreatic Surgery, Japan Society for Endoscopic Surgery. He has organized the international difficulty score meeting for minimally invasive pancreatic resection in APHPBA 2017, and its fruits are preparing for publishing. His research interest is pancreatic cancer and pancreatic surgery. He has published more than 100 original papers in international journals about cancer biology and clinical studies focusing on pancreatic cancer and pancreatic surgery. His current topics are multidisciplinary therapy for advanced pancreatic cancer, minimally invasive pancreatic surgery and IPMN. He is a fellow of the American College of Surgeons, a Councilor of Asian Surgical Association, and a Councilor of Japanese several surgical and oncological societies including Japan Surgical Society. He is the Vice Editor-in-Chief of Journal of Japan Society for Endoscopic Surgery, an Editorial board of JHBPS, JLAST and IJCO.
Associate Professor, Department of Surgery and Oncology, Kyushu University, Fukuoka, Japan. E-mail; email@example.com
1994 MD, Kyushu University.
1999 Research Fellow, Department of Surgery and Oncology, Kyushu University.
2001 Research Fellow, Cancer Biology Program, Harvard University, MA, USA.
2004 PhD, Kyushu University
2009 Assistant Professor, Department of Surgery and Oncology, Kyushu University
Tanaka M, Fernández-del Castillo C, Ohtsuka T, et al. Revisions of international consensus Fukuoka guidelines for the management of IPMN of the pancreas. Pancreatology, 17; 738-753, 2017.
Date K, Ohtsuka T, et al. Molecular evidence for monoclonal skip progression in MD-IPMNs of the pancreas. Ann Surg 265; 969-977, 2017.
Segersvard R, Ohtsuka T, Rangelova E, Tanaka M. Comparison between IAP and European guidelines for the management of cystic lesions of the pancreas. In: Chiaro MD, et al (ed): Cystic Tumors of the Pancreas. 171-175, Springer, Switzerland, 2016.
Dr. Eileen M. O’Reilly serves as the Associate Director for Clinical Research for the David M. Rubenstein Center for Pancreas Cancer and is an Attending Physician and Member at Memorial Sloan-Kettering Cancer Center (MSKCC) in New York and Professor of Medicine at Weill Cornell Medical College. Dr. O’Reilly has pancreatic and hepatobiliary malignancies as the major focus of her research and clinical activities. Research initiatives include integration of molecular and genetic-based therapies for the treatment of pancreas cancer along with identification of biomarkers that maybe used to select therapy. Dr. O’Reilly is the Principal Investigator of multiple phase I, II and III trials in pancreas cancer and has authored many articles, editorials and book chapters. Dr. O’Reilly’s institutional responsibilities include Associate Chairpersonship of MSKCC’s Institutional Review & Privacy Board (IRB), Chair of the Data and Safety Monitoring Committee (DSMC) and Chair of the Continuing Medical Education (CME) committee. Nationally, Dr. O’Reilly is the Co-Chair of the Alliance Co-Operative Group Gastrointestinal Cancers Committee, and serves on the Gastrointestinal Cancers Steering Committee (GISC), Scientific Advisory Board of the Pancreatic Cancer Action Network, NCCN Pancreas panel and the Board of the National Pancreas Foundation.
Dr. Nickolas Papadopoulos is internationally known as a co‐discoverer of the genetic basis of the predisposition to hereditary nonpolyposis colon cancer (HNPCC), one of the most common hereditary forms of cancer, earlier in his career. He is known for the development of diagnostic tests and he is considered an expert in cancer genetics and diagnostics. He was part of the interdisciplinary team that was first to sequence all of the protein coding genes, determine genetic alterations and construct expression profiles in multiple tumors of different cancer types. Currently, he is focused on translating the genetic information derived from cancer genome analyses to clinical applications in early detection, diagnosis and monitoring of cancer. He is a co-developer of sensitive methods for the detection of tumor DNA in liquid biopsy. He is also the co-founder of two companies that develop diagnostics for cancer.
Dr. Park is an Assistant Professor of Medicine at Stanford University, where he is Medical Director of the Pancreas Clinic within the Stanford Digestive Health Center. As a pancreatologist, he focuses on the diagnosis and management of a spectrum of pancreatic conditions including acute and chronic pancreatitis to pre-malignant pancreatic cysts. His research focuses on developing and validating novel biomarkers for early diagnosis of advanced cystic neoplasms and early pancreas cancer. He is a Principal Investigator within the NIH Consortium for the Study of Chronic Pancreatitis, Diabetes, and Pancreas Cancer (CPDPC), and Pancreatic Cancer Detection Consortium (PCDC).
Dr. Vincent J Picozzi, MD MMM directs the Pancreas Center of Excellence at Virginia Mason. A Yale University graduate (summa cum laude, Phi Beta Kappa), Dr. Picozzi trained at Stanford and Harvard University (Brigham and Women’s Hospital), and holds a MMM degree, Delta Omega, (Tulane University).
Dr. Picozzi has one of the largest US pancreaticobiliary oncology practices . He has received numerous clinician accolades, directs an active clinical research program, has published over 100 papers and abstracts, and has been a featured speaker at virtually every major national clinical oncology meeting.
Dr. Picozzi has recently held national leadership positions including Educational Chair for Non-Colorectal Cancers (ASCO and the GI Oncology Symposium 2016), the Executive Committees of the Pancreas Cancer Research Team (PCRT) and Pancreatic Cancer Action Network (PANCAN) (Past Chairman and current Clinical Initiatives Committee Chair). He is co-principal investigator and Clinical Trials Consortium Chairman for the Precision Promise project.
Dr. Michelle Reid is a cytopathologist and surgical pathologist with subspecialty expertise in pancreatobiliary tract pathology who has been in practice for more than 10 years. After completing a cytopathology fellowship at Memorial Sloan Kettering Cancer Center in 2005, she joined the faculty at Medical College of Georgia and later Emory University Hospital in 2010. She is currently Professor of Pathology, Director of Cytopathology and Director of the Cytopathology Fellowship at Emory University Hospital. Dr. Reid has numerous peered-reviewed journal publications and book chapters on pancreatobiliary tract pathology. She has given courses, workshops and invited lectures on pancreatobiliary pathology at various national and international venues including the USCAP, CAP, ASCP, ASC, ECP and the IAP. Her experience and expertise as a cytopathologist and surgical pathologist with research interest in pancreatobiliary pathology give her a unique perspective on the challenges faced by pathologists who routinely interpret these specimens, as well as the importance of accurate diagnosis of lesions involving these sites, through the identification of key discerning cyto-histomorphologic features that will allow for better classification and prognostication of tumors.
Dr. Rocha is a surgical oncologist and hepatopancreatobiliary surgeon in the Section of General, Thoracic and Vascular Surgery and Director of Research in the Digestive Disease Institute at Virginia Mason Medical Center. He also holds an appointment as a Clinical Assistant Professor of Surgery at the University of Washington. He attended the Pritzker School of Medicine at the University of Chicago. He then completed a residency in general surgery and postdoctoral fellowship in tissue engineering at the Brigham and Women’s Hospital. After residency, he pursued a surgical oncology and hepatopancreatobiliary surgery fellowship at Memorial Sloan-Kettering Cancer Center in New York City. His clinical practice involves benign and malignant disease of the liver, bile ducts and pancreas. As an investigator at the Benaroya Research Institute, his research is focused on biomarker discovery and novel therapeutics in pancreaticobiliary cancer. He has been funded by ASCO and the Cholangiocarcinoma Foundation. He currently serves on the editorial boards of HPB, Journal of Surgical Oncology and PLoS ONE. He is also a member of several surgical societies including the SSO, AHPBA, and SSAT. He serves on the Pancreas Task Force at the NCI and sits on the executive committee of the International Cholangiocarcinoma Research Network.
Prof. Scarpa is Chair of the Department of Pathology at Verona University and Director of the ARC-Net Centre for applied research on cancer at Verona University, Italy. He is leader of the Italian effort in the International Cancer Genome Consortium funded by the Italian Ministry of Research and Ministry of Health, Coordinator of the Italian National Consortium for innovative molecular diagnostics in pancreas cancer funded by the Associazione Italiana per la Ricerca sul Cancro (AIRC). The research focus of Prof. Scarpa is the translation into clinical practice of molecular subclassifications of cancers with prognostic-therapeutic relevance. He has published over 400 peer-reviewed papers. His interest in neuroendocrine neoplasms dates back to 1992 and ranges from histopathology and staging/grading to molecular characterisation.
Thomas J. Smith MD FACP FASCO FAAHPM
Harry J. Duffey Family Professor of Palliative Medicine and
Director of Palliative Medicine, Johns Hopkins Medical Institutions
Professor of Oncology, Sidney Kimmel Comprehensive Cancer Center
600 N. Wolfe Street, Blalock 369
Baltimore, MD 21287-0005
Phone 410-955-2091; Fax 410-955-2098; Cell 443-742-5978
University of Akron, B.S., summa cum laude 1971-74
Yale University School of Medicine, M.D. cum laude 1974-79
Yale University School of Organization and Management (core curriculum, one year) 1977-78
Special Visiting Fellow, National Cancer Center Biological Response Modifiers Program, Frederick, MD 1986
Virginia Commonwealth University Fellowship in Hematology/Oncology 1982-87
Project on Death in America Faculty Scholar, 1995-98
Professor of Oncology, Sidney Kimmel Comprehensive Cancer Center of Johns Hopkins, and the Harry J. Duffey Family Professor of Palliative Medicine, and Director of Palliative Medicine, Johns Hopkins Medical Institutions, Baltimore, MD.
Dr. Smith is an oncologist and palliative care specialist with a lifelong interest in better symptom management and improving access to high quality affordable care. He is the Director of Palliative Medicine for Johns Hopkins Medicine, charged with integrating palliative care into all the Johns Hopkins venues. The PC consult service sees over 1500 new patients a year, and a research agenda with “Scrambler Therapy” for pain, palliative care for patients on Phase I drug trials, topical gapabentin to prevent neuropathy (CIPN), and others.
Dr. Smith has been recognized in “Best Doctors in America” for many years and is a Fellow in the American College of Physician, the American Society of Clinical Oncology and the American Academy of Hospice and Palliative Medicine. He received the ACS Trish Greene Award for “outstanding research that benefits cancer patients and their families” and was recognized as a “Visionary in Palliative Care” by AAHPM.
Grace Saunders is the President of the Joseph C. Monastra (JCM) Foundation for Pancreatic Cancer Research as well as a member and advocate of the World Pancreatic Cancer Coalition (WPCC). Grace has been the President of the JCM Foundation for the past 10 years. In the last meeting with the WPCC in Montreal, Grace participated in extensive discussions with many pancreatic cancer advocacy organizations. Over the 15 years with the JCM Foundation, she has worked with pathologists and scientists at John Hopkins Health Institutes and Emory University to continue to increase funding for pancreatic cancer research. She has worked at a local level in multiple different cities and is currently establishing new fundraisers in Chicago. The World Pancreatic Cancer Coalition was started in 2013 and has more than 70 foundations organizing activities in patient advocacy, services, education, and research. WPCC’s goal is to bring together pancreatic cancer patient advocacy organizations from around the world to discuss working together to raise global pancreatic cancer awareness and work collaboratively to support each other’s effort.
Tyler Saunders is a 4th year medical student, grandson of Joseph C. Monastra, and advocate for the Joseph C. Monastra (JCM) Foundation for Pancreatic Cancer Research. Tyler is concluding his medical school education and going to start residency in July in Internal Medicine in Chicago. His career goals currently are focused on lifestyle as the staple of medical care and prevention of disease. Before starting medical school, Tyler worked at John Hopkins in the lab of Christine Iacobuzio MD, PhD and Christopher Wolfgang MD, PhD. When Tyler was eleven his grandfather, Joseph C. Monastra, was diagnosed with Stage 4 pancreatic cancer. His grandfather’s influence continues to have tremendous impact on his life and career goals. Tyler’s story describes how pancreatic cancer and the formation of this foundation have changed his life. The JCM Foundation was started fifteen years ago and continues to raise money for early detection and awareness of pancreatic cancer. The foundation has recently joined the World Pancreatic Cancer Coalition, the largest group of pancreatic cancer foundations in the world.
Kyoichi Takaori, M.D., Ph.D., F.A.C.S. Head, Pancreas Cancer Unit
Kyoto University Hospital
Dr. Kyoichi Takaori is a pancreatic surgeon who has extensive experiences of open, laparoscopic, and robotic surgery. His academic career includes Professor of Surgery at Asahi University and Assistant Professor of Physiology and Biophysics at University of Arkansas for Medical Sciences. Throughout his career, he has struggled to improve the prognosis of pancreatic cancer, which is known as the worst malignancy. First, he has focused on early detection of pancreatic cancer and founded a Japanese Familial Pancreatic Cancer Registry in 2013. Second, he has endeavored to accelerate innovation in pancreatic surgery. In order to increase resectability and to improve local control, he has refined artery-first pancreatoduodenectomy by utilizing the “Tiger’s Den approach” and developed new techniques of artery-first distal pancreatectomy and artery-first DP-CAR. Third, he is a great believer of multi-disciplinary approach and presently directing the multi-disciplinary team as the Head of Pancreatic Cancer Unit at Kyoto University Hospital.
David Ting is currently a gastrointestinal medical oncologist at the Massachusetts General Hospital (MGH) Cancer Center and assistant professor of medicine at Harvard Medical School. After receiving his B.S. in chemical engineering and biology from MIT, he completed his medical degree at Harvard Medical School with magna cum laude honors. During his undergraduate and medical school studies, he trained with Dr. Robert Langer at MIT on drug delivery platforms and did a HHMI fellowship with Dr. George Daley formerly at the Whitehead Institute on hematopoietic stem cells. He completed internal medicine residency at the MGH and medical oncology fellowship in the combined Dana-Farber Cancer Institute and MGH Cancer Center program. He moved on to post-doctoral training with Daniel Haber’s group at the MGH Cancer Center characterizing pancreatic circulating tumor cells (CTCs) and primary tumors with RNA-sequencing. His work revealed aberrant expression of non-coding satellite RNAs in pancreatic cancer as a potential novel cancer biomarker, and he has characterized the transcriptional programs in pancreatic CTCs with single cell RNA sequencing. He currently runs his own independent group at the MGH Cancer Center with a focus on CTCs and non-coding RNAs in gastrointestinal cancers as novel biomarkers and therapeutic targets.
William Traverso, MD, FACS is a graduate of the UCLA Medical School (1973), and Surgery Residency (UCLA, 1978). He has authored more than 250 articles on the treatment of pancreatic and biliary diseases.
He is past president of the Society for Surgery of the Alimentary Tract (SSAT), Society of the American Gastrointestinal Endoscopic Surgeons (SAGES), North Pacific Surgical Association (NPSA), and the American College of Surgeons, Washington Chapter. He was co-director of the Pancreas Club for 15 years.
Until his retirement in July 2015 Dr. Traverso served as the Director for the Center for Pancreatic Diseases for 5 years (St. Luke’s Health Care System, Boise) following 25 years at the Virginia Mason Medical Center in Seattle. Since 2001 along with his Virginia Mason colleagues in gastroenterology and medical oncology, he has organized the Pancreas Cancer International Conferences in Seattle (2001), Pisa (2005), Rome (2009), Kyoto (2011), Verona (2014) and Glasgow (2016).
David Tuveson is Director of the Cancer Center and the Roy J. Zuckerberg Professor of Cancer Research at Cold Spring Harbor Laboratory, and the Chief Scientist at the Lustgarten Foundation. Dr. Tuveson obtained a bachelors degree in chemistry at M.I.T., followed by M.D. and Ph.D. degrees at Johns Hopkins. Dr. Tuveson was a medical resident at Brigham and Women’s Hospital and a medical oncology fellow at Dana-Farber/Harvard Cancer Center. During his post-doctoral years in Boston, Dr. Tuveson co-developed KIT inhibitors for gastrointestinal stromal tumors with George Demetri. Simultaneously, he generated several widely-used mouse cancer models with Tyler Jacks. As an independent investigator, his lab developed the first mouse models of ductal pancreatic cancer at the University of Pennsylvania. Subsequently, Dr. Tuveson was recruited to the University of Cambridge to develop preclinical and clinical therapeutic strategies for pancreatic cancer. In Cambridge, his lab identified a variety of parameters that limit therapeutic efficacy in pancreatic cancer, including poor drug delivery and survival factors in the microenvironment. Dr. Tuveson returned to the USA to direct the Cancer Therapeutics Initiative at CSHL and to serve as Director of Research for the Lustgarten Foundation. He continues to practice medical oncology with an adjunct appointment at MSKCC. His awards include the Rita Allen Scholarship and the Jan Waldenström Award, and the Hamdan Award.
Dr. Bert Vogelstein attended the University of Pennsylvania, where he graduated with distinction in mathematics. He obtained his medical degree at the Johns Hopkins University School of Medicine and performed his residency in pediatrics at the Johns Hopkins Hospital. Following his clinical training, Dr. Vogelstein completed a post-doctoral fellowship at the National Cancer Institute, focusing on the development of new approaches to study human cancers. He is currently the Do-Director of the Ludwig Center for Cancer Genetics & Therapeutics at the Johns Hopkins Kimmel Cancer Center, a Lustgarten Foundation Distinguished Scholar, and an Investigator of the Howard Hughes Medical Institute.
Dr. Vogelstein’s current research focuses on the genetic basis of human cancers and the use of this knowledge to improve diagnosis and management of patients with these diseases. He is a member of the American Academy of Arts & Sciences, the National Academy of Sciences, the American Philosophical Society, the National Academy of Medicine and the European Molecular Biology Organization (EMBO). His advisory roles have included Chairmanships of the National Research Council Committee on the Biological and Biomedical Applications of Stem Cell Research and the Board of Scientific Counselors of the National Human Genome Research Institute.
Matthew John Weiss, MD
Associate Professor of Surgery
Director, Complex Surgical Oncology Fellowship
Surgical Director, Liver and Pancreas Multidisciplinary Clinics
Matthew Weiss, MD, FACS is an Associate Professor of Surgery at the Johns Hopkins University School of Medicine. He is board-certified in general surgery and dual fellowship-trained in both complex surgical oncology and hepatopancreatobiliary (liver, pancreas and bile ducts) surgery. He trained in general surgery at the Johns Hopkins Hospital and completed a research fellowship at the Massachusetts General Hospital in immunology. He completed clinical fellowships at Memorial Sloan-Kettering Cancer Center in both surgical oncology and hepatopancreatobiliary surgery. His clinical interests include both benign and malignant tumors of the pancreas, liver, bile ducts, and gallbladder.
Dr. Jordan M. Winter received his undergraduate degree in Chemistry from Princeton University and attended the Weill Medical College of Cornell University. He trained in General Surgery at Johns Hopkins, and spent additional years as a post-doctoral research fellow in Oncology. Dr. Winter received specialty fellowship training in Surgical Oncology at the Memorial Sloan-Kettering Cancer Center. In 2011, Dr. Winter was recruited as an Assistant Professor of Surgery at Thomas Jefferson University and was promoted to Associate Professor in 2014. He serves as a Co-Director of the Jefferson Pancreas, Biliary and Related Cancer Center, the GI Multidisciplinary Group in the Sidney Kimmel Cancer Center, and the Multidisciplinary Pancreas Cancer Clinic. Dr. Winter’s clinical interest is in the management of pancreatic and related cancers. He has led clinical oncology trials, and maintains a basic science lab, funded by the NIH, American Cancer Society, and industry.
Christopher L. Wolfgang, MD, PhD is the Chief of the Division of Hepatobiliary and Pancreas Surgery and the Vice Chair for Surgical Oncology at Johns Hopkins. He is the John L. Cameron Professor of Surgery and holds secondary appointments as a Professor of Pathology and Oncology. Dr. Wolfgang graduated from Temple School of Medicine in 1998 with a combined MD/PhD degree (biochemistry) and completed his residency in 2004 at Penn State. He went on to complete an Assistant Chief of Service fellowship in advanced gastrointestinal surgery in 2005. He has remained at Johns Hopkins ever since and spends the majority of his time as a clinical surgeon with a focus on pancreatic neoplasms. In addition, he leads a research group focused on understanding the biology of pancreatic cancer and cystic neoplasms of the pancreas.
Dr. Wolpin is a medical oncologist and translational cancer researcher at Dana-Farber Cancer Institute and Harvard Medical School (Boston, MA). He obtained his M.D. from Harvard Medical School and completed a residency in internal medicine at Brigham and Women’s Hospital. He completed fellowship training in medical oncology at Dana-Farber Cancer Institute (DFCI) and returned to Brigham and Women’s hospital to serve as chief medical resident. Subsequently, he received a M.P.H. from Harvard School of Public Health. His research program is focused on understanding the factors that promote initiation and progression of pancreatic ductal adenocarcinoma. These studies involve evaluation of blood-based circulating markers, germline alterations, and somatic alterations in hundreds to thousands of subjects. Dr. Wolpin is Director of the Gastrointestinal Cancer Center and Director of the Hale Center for Pancreatic Cancer Research at DFCI, and an Associate Professor of Medicine at Harvard Medical School. He also serves as co-Principal Investigator for the Pancreatic Cancer Cohort Consortium, director of a large pancreatic cancer biospecimen bank at DFCI, and Director of the Pancreas and Biliary Tumor Center at Dana-Farber/Brigham and Women’s Cancer Center. His research has been funded by the National Cancer Institute, Howard Hughes Medical Institute, Lustgarten Foundation, ASCO Conquer Cancer Foundation, Pancreatic Cancer Action Network, and U.S. Department of Defense. Dr. Wolpin’s clinical practice involves the care of patients with gastrointestinal cancers, with a particular focus on pancreatic cancer. He has held several leadership positions related to clinical expertise, including membership on the Alliance/CALGB Gastrointestinal Cancer Committee, NCCN Guidelines Committee for Pancreatic Adenocarcinoma, and National Cancer Institute Pancreas Cancer Task Force.
Laura D. Wood, MD, PhD is an Assistant Professor in the Department of Pathology, Division of Gastrointestinal and Liver Pathology at the Johns Hopkins University School of Medicine. Dr. Wood received her BS in Biology from the College of William & Mary, graduating Summa Cum Laude with membership in Phi Beta Kappa. She then went on to earn both her MD and PhD from The Johns Hopkins University School of Medicine, with membership in Alpha Omega Alpha. She completed her PhD research in the laboratory of Dr. Bert Vogelstein, where she led the first whole exome sequencing studies in human cancers. Dr. Wood then went on to complete residency in Anatomic Pathology (serving as Chief Resident in her final year) and fellowship in Gastrointestinal and Liver Pathology at The Johns Hopkins Hospital. Now, she leads her own basic science laboratory focused on molecular characterization of pancreatobiliary cancers and their precursor lesions. In addition, she signs out clinical specimens on the Gastrointestinal and Liver Pathology services.
Dr. Hiroki Yamaue graduated Wakayama Medical University in 1981. He received PhD degree in 1989 from Wakayama Medical University. After graduation, he trained HBP surgery, especially pancreatic surgery.
In 2001, he was appointed as Professor of Second Department of Surgery. From 2014 to 2017, He has been additionally appointed the Director of Education and Research of the Wakayama Medical University.
He is currently Professor of Second Department of Surgery（Division of Digestive surgery）, Wakayama Medical University School of Medicine in Wakayama, Japan, Where he is also the Director of Wakayama Medical University Hospital from 2017.
He has been actively involved in the basic and clinical research of pancreatic cancer. His major interest of research is treatment of pancreatic cancer. He has been interested not only in surgery but also in Cancer Immunology.
He has contributed extensively in professional activities in his area of expertise.
He has published more than 400 papers in peer-reviewed journals including Annals of surgery and has conducted many clinical trials.
Jun Yu, MD, PhD is an Assistant Professor in the Department of Surgery, Division of Hepatobiliary and Pancreas Surgery at the Johns Hopkins University School of Medicine. He is the Chief Scientist of Division of Hepatobiliary and Pancreas Surgery at Johns Hopkins. Dr. Yu received his medical degree from Gannan Medical University and a PhD in Surgery and Oncology from Kyushu University School of Medicine. His research focuses on understanding the biology of pancreatic cancer and cystic neoplasms of the pancreas, and on detecting the actionable mutations/pathways for the patients with pancreatic cancer in a personalized therapeutic strategy. He developed several novel sequencing technologies, including digital Next-Generation Sequencing (dNGS) and Single-cell Next-Generation Sequencing (scNGS). He is the Principle Investigator of the Pancreatic Cancer Precision Medicine Center of Excellence (PMCoE) at Johns Hopkins. In addition, he serves as a Committee Member of the Clinical Research Review Committee at the Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins.
Herbert J. Zeh III
Herbert J. Zeh III, MD, is chief of the Division of Gastrointestinal (GI) Surgical Oncology at UPMC CancerCenter, Associate Director of UPMC Hillman Cancer Center, Senior Director of UPMC Surgical Services and Watson Family Professor of Surgery. Dr. Zeh specializes in cancers and diseases of the stomach, liver, pancreas, and duodenum, and practices state-of-the-art robotic technology.
Board-certified in surgery, Dr. Zeh received a medical degree from the University of Pittsburgh School of Medicine. He completed post-graduate training in advanced GI surgery and surgical oncology at The Johns Hopkins Hospital in Baltimore, where he served as senior and chief resident, as well as the Society of Surgical Oncology fellow. Dr. Zeh served as a surgical oncology medical staff fellow at the National Cancer Institute – Surgery Branch in Bethesda, MD.
Dr. Zeh is a member of several professional organizations, including the American Surgical Association (ASA), Society of Surgical Oncology (SSO), American Society of Clinical Oncology (ASCO), the Society of University Surgeons (SUS), and the Pancreas Club. Dr. Zeh had authored over 110 peer reviewed articles and book chapters. He directs a translational research laboratory examining Damage Associated Molecular Pattern molecules (DAMP) in the setting of pancreatic cancer. In addition, Dr. Zeh is principle investigator on several Phase I and II clinical trials in pancreatic cancer. Dr. Zeh, together with his team at UPMC, has accumulated one of the world’s largest experiences with robotic assisted pancreatic resections.
Lei Zheng, M.D., Ph.D. is an associate professor of Oncology and Surgery in the Gastrointestinal Oncology Program at the Johns Hopkins University School of Medicine and lead a large translational program that focuses on the preclinical and clinical development of novel vaccine- and antibody-based rational combination immunotherapy for gastrointestinal cancers at the Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins. He is Co-director of the Pancreatic Cancer Precision Medicine Program, a Pancreatic Cancer Center of Excellence (PMCoE) program at Johns Hopkins and also leads a personalized immunotherapy/relational database program at the Bloomberg-Kimmel Institute for Cancer Immunotherapy. His clinical work is focused on multidisciplinary management for pancreatic cancer, bile duct cancer, liver metastases, and gastric cancer. He is the founding Editor-in-Chief of Annals of Pancreatic Cancer.